{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH1%2FIDH2+Mutation", "query": { "condition": "IDH1/IDH2 Mutation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH1%2FIDH2+Mutation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T22:28:06.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03914742", "title": "BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "IDH1 Mutation", "IDH2 Mutation", "Recurrent Glioblastoma", "Recurrent WHO Grade II Glioma", "Recurrent WHO Grade III Glioma" ], "interventions": [ { "name": "PARP Inhibitor BGB-290", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2020-02-16", "completion_date": "2023-10-31", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03914742" }, { "nct_id": "NCT07629089", "title": "VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "Vorasidenib", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Megan Mantica", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-06-30", "completion_date": "2035-06-30", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07629089" }, { "nct_id": "NCT02677922", "title": "A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "AG-120", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "AG-221", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2016-06-03", "completion_date": "2026-09-30", "has_results": true, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 9, "location_summary": "Duarte, California • New Haven, Connecticut • Chicago, Illinois + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677922" }, { "nct_id": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Newly Diagnosed Acute Myeloid Leukemia (AML)", "Untreated AML", "AML Arising From Myelodysplastic Syndrome (MDS)", "AML Arising From Antecedent Hematologic Disorder (AHD)", "AML Arising After Exposure to Genotoxic Injury" ], "interventions": [ { "name": "AG-120", "type": "DRUG" }, { "name": "AG-221", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2015-12-31", "completion_date": "2026-07-24", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632708" }, { "nct_id": "NCT02071862", "title": "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Triple-Negative Breast Cancer", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Mesothelioma", "Fumarate Hydratase (FH)-Deficient Tumors", "Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)", "Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors", "Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations", "Tumors Harboring Amplifications in the cMyc Gene" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Pac-CB", "type": "DRUG" }, { "name": "CBE", "type": "DRUG" }, { "name": "CB-Erl", "type": "DRUG" }, { "name": "CBD", "type": "DRUG" }, { "name": "CB-Cabo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2014-02", "completion_date": "2019-03", "has_results": false, "last_update_posted_date": "2022-07-20", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 13, "location_summary": "San Francisco, California • Stanford, California • Sarasota, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071862" }, { "nct_id": "NCT03749187", "title": "BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "IDH1 Gene Mutation", "IDH2 Gene Mutation", "Low Grade Glioma", "Malignant Glioma", "Recurrent Glioblastoma", "Recurrent WHO Grade II Glioma", "Recurrent WHO Grade III Glioma", "WHO Grade II Glioma", "WHO Grade III Glioma" ], "interventions": [ { "name": "PARP Inhibitor BGB-290", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "13 Years to 39 Years" }, "enrollment_count": 78, "start_date": "2019-04-03", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03749187" }, { "nct_id": "NCT03212274", "title": "Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Glioblastoma", "Recurrent Cholangiocarcinoma", "Recurrent Glioma", "Recurrent Malignant Solid Neoplasm", "WHO Grade 2 Glioma", "WHO Grade 3 Glioma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2019-01-30", "completion_date": "2026-07-28", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 51, "location_summary": "Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03212274" }, { "nct_id": "NCT04164901", "title": "Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Grade 2 Glioma", "Residual Glioma", "Recurrent Glioma" ], "interventions": [ { "name": "Vorasidenib", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 331, "start_date": "2020-01-05", "completion_date": "2028-05", "has_results": true, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164901" }, { "nct_id": "NCT06478212", "title": "Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "IDH1-mutant Glioma", "IDH2-mutant Glioma" ], "interventions": [ { "name": "Vorasidenib", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 51, "start_date": "2025-01-22", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 6, "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06478212" }, { "nct_id": "NCT06666712", "title": "Chronic CED of TPT for Recurrent Malignant Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumor, Recurrent", "Malignant Glioma (WHO Grade III or IV)", "IDH1/IDH2 Mutation" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey N. Bruce", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2026-06-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-06-25T22:28:06.508Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06666712" } ] }